(Circulation. 2000;102:1634.)
© 2000 American Heart Association, Inc.
Clinical Investigation and Reports |
From the Institute for Prevention of Cardiovascular Disease, Cardiovascular Division, Beth Israel Deaconess Medical Center, Harvard Medical School (J.J.S., G.H.T., I.L., JE.M.); Boston University, Mathematics and Statistics Department (H.S., R.B.DA.); and Boston University School of Public Health, Department of Epidemiology and Biostatistics (J.M.M.), Boston, Mass; and the National Heart, Lung and Blood Institutes, Framingham Heart Study and National Institutes of Health (T.H.M., P.S., P.F.W.W.), Framingham, Mass.
Correspondence to Ralph B. DAgostino, PhD, Boston University, Mathematics and Statistics Department, 111 Cummington St, Boston, MA 02215. E-mail ralph{at}bu.edu
BackgroundFibrinogen has been identified as an independent risk factor for cardiovascular disease and associated with traditional cardiovascular risk factors. Also, the role of elevated fibrinogen in thrombosis suggests that it may be on the causal pathway for certain risk factors to exert their effect. These associations remain incompletely characterized. Moreover, the optimal fibrinogen assay for risk stratification is uncertain.
Methods and ResultsIn 2632 subjects from cycle 5 of the Framingham Offspring Population, fibrinogen levels were determined with a newly developed immunoprecipitation test (American Biogenetic Sciences) and the functional Clauss method. With the immunoprecipitation method, there were significant linear trends across fibrinogen tertiles (P<0.001) for age, body mass index, smoking, diabetes mellitus, total cholesterol, HDL cholesterol, and triglycerides in men and women. The Clauss method had significant results (P<0.030), except for triglycerides in men. Fibrinogen levels were higher for those with compared with those without cardiovascular disease. After covariate adjustment, fibrinogen remained significantly higher in those with cardiovascular disease with the use of the immunoprecipitation test (P=0.035 and P=0.018 for men and women, respectively) but not with the Clauss method.
ConclusionsFibrinogen was associated with traditional cardiovascular risk factors. Elevation of fibrinogen may provide a mechanism for risk factors to exert their effect. Also, fibrinogen levels were higher among subjects with cardiovascular disease compared with those without disease. The immunoprecipitation test showed a stronger association with cardiovascular disease than the Clauss method, suggesting that it may be a useful screening tool to identify individuals at increased thrombotic risk.
Key Words: fibrinogen cardiovascular disease Framingham Offspring Study
This article has been cited by other articles:
![]() |
I. Mertens, R. V Considine, M. Van der Planken, and L. F Van Gaal Hemostasis and fibrinolysis in non-diabetic overweight and obese men and women. Is there still a role for leptin? Eur. J. Endocrinol., September 1, 2006; 155(3): 477 - 484. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Feinbloom and K. A. Bauer Assessment of Hemostatic Risk Factors in Predicting Arterial Thrombotic Events Arterioscler Thromb Vasc Biol, October 1, 2005; 25(10): 2043 - 2053. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Soria, L. Almasy, J. C. Souto, A. Buil, M. Lathrop, J. Blangero, and J. Fontcuberta A Genome Search for Genetic Determinants That Influence Plasma Fibrinogen Levels Arterioscler Thromb Vasc Biol, June 1, 2005; 25(6): 1287 - 1292. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. B. Loucks, L. F. Berkman, T. L. Gruenewald, and T. E. Seeman Social Integration Is Associated With Fibrinogen Concentration in Elderly Men Psychosom Med, May 1, 2005; 67(3): 353 - 358. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Arikan and S. Sen Endothelial Damage and Hemostatic Markers in Patients with Uncomplicated Mild-to-Moderate Hypertension and Relationship with Risk Factors Clinical and Applied Thrombosis/Hemostasis, April 1, 2005; 11(2): 147 - 159. [Abstract] [PDF] |
||||
![]() |
I. J. Kullo and C. M. Ballantyne Conditional Risk Factors for Atherosclerosis Mayo Clin. Proc., February 1, 2005; 80(2): 219 - 230. [Abstract] [PDF] |
||||
![]() |
E.-G. V. Giardina, H. J. Chen, R. R. Sciacca, and L. E. Rabbani Dynamic Variability of Hemostatic and Fibrinolytic Factors in Young Women J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 6179 - 6184. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. H Reinhart Fibrinogen - marker or mediator of vascular disease? Vascular Medicine, August 1, 2003; 8(3): 211 - 216. [Abstract] [PDF] |
||||
![]() |
R. L. Klein, S. J. Hunter, A. J. Jenkins, D. Zheng, A. J. Semler, J. Clore, W. T. Garvey, and The DCCT/EDIC Study Group Fibrinogen Is a Marker for Nephropathy and Peripheral Vascular Disease in Type 1 Diabetes: Studies of plasma fibrinogen and fibrinogen gene polymorphism in the DCCT/EDIC cohort Diabetes Care, May 1, 2003; 26(5): 1439 - 1448. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Vlassara, W. Cai, J. Crandall, T. Goldberg, R. Oberstein, V. Dardaine, M. Peppa, and E. J. Rayfield Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy PNAS, November 26, 2002; 99(24): 15596 - 15601. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. ZANOBETTI and J. SCHWARTZ Are Diabetics More Susceptible to the Health Effects of Airborne Particles? Am. J. Respir. Crit. Care Med., September 1, 2001; 164(5): 831 - 833. [Abstract] [Full Text] [PDF] |
||||
![]() |
K.G. Jones, D.J. Brull, L.C. Brown, M. Sian, R.M. Greenhalgh, S.E. Humphries, and J.T. Powell Interleukin-6 (IL-6) and the Prognosis of Abdominal Aortic Aneurysms Circulation, May 8, 2001; 103(18): 2260 - 2265. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2000 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |